RxDoctor Payments Data

Arthur An, MD

Neurology · Arcadia, CANPI 1649293259

Payments from drug & device makers

$10,250in general payments, 2019–2025

Across 421 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • Amgen$815
  • UCB, Inc.$804
  • Teva Pharmaceuticals USA, Inc.$586
  • AstraZeneca$460
  • plus $4K from 44 others

What the payments were for

  • Speaking & faculty fees$490%
  • Food & beverage$9,99497%
  • Education$2082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,250 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$155,886
Medicare patients
281
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$136,551
KeppraLevetiracetam11$33,362
RytaryCarbidopa/Levodopa26$25,701
BotoxOnabotulinumtoxina26$23,977
NourianzIstradefylline12$21,602
Memantine Hcl482$14,879
XadagoSafinamide Mesylate13$14,087
Penicillamine13$9,531
Gabapentin543$9,311
Levetiracetam171$6,593
Carbidopa-LevodopaCarbidopa/Levodopa143$3,484
Duloxetine Hcl129$2,798
Divalproex Sodium43$2,627
Pramipexole DihydrochloridePramipexole Di-Hcl126$2,271
Midodrine Hcl12$2,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$80$136,55117 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$231$27,41572 claims
AbbVieBotox$1,752$23,97726 claims
Upsher-smith Laboratories LLCTopiramate$21$1,12751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →